SternAegis Ventures

DarioHealth, established in 2011 and headquartered in Caesarea, Israel, is a digital health company specializing in the development and commercialization of patented technologies for mobile, real-time health monitoring. Its flagship product, Dario, is a comprehensive diabetes management solution comprising a pocket-sized blood glucose monitoring device and a multi-featured software application. DarioHealth markets its products directly to consumers and through retail channels, generating revenue primarily from the sale of its smart meters and related disposable test strips and lancets. The company's digital platform, DarioEngage, engages users, provides coaching and support, and offers real-time alerts and trend analysis for chronic illness management. DarioHealth operates internationally, with a presence in the United States, Europe, Australia, and Canada.

Laconic Enterprises, LLC is a specialty firm based in Toronto, Canada, dedicated to infrastructure development in the energy sector. The company focuses on constructing and managing projects aimed at addressing critical energy availability challenges faced by governments and government-sponsored enterprises around the world. Through its expertise in high-value-add projects, Laconic Enterprises seeks to provide effective solutions to enhance energy access and reliability on a global scale.

Zoomcar is a leading car-sharing marketplace operating primarily in emerging markets, with over 20,000 cars available on its technology-driven platform across India, Southeast Asia, and Egypt. The company enables host entrepreneurs to share their vehicles safely and easily, generating additional passive income. Guests benefit from a wide range of affordable cars for memorable driving experiences. Founded in 2013 and based in Bengaluru, India, Zoomcar employs over 300 people and serves 50 cities across India, Indonesia, Vietnam, and Egypt. Uri Levine, co-founder of mobility companies Waze and Moovit, is the Chairman of the Board. The company's revenue comes mainly from short-term self-drive rentals and vehicle subscriptions, with a significant portion derived from its operations in India.

Super League Enterprise Inc. operates an amateur esports content network that focuses on creating and distributing engaging content across various platforms, including social media and live streaming. Based in Santa Monica, California, the company hosts recreational video game league events in movie theaters, providing gamers with unique experiences, particularly through its popular Minecraft events. Super League has expanded its offerings by partnering with Riot Games to introduce new competitive events like City Champs and City Rec League of Legends, encouraging local players to compete and socialize in a vibrant environment. The company also develops immersive content experiences and media solutions, reaching large audiences in digital spaces. Its revenue streams include advertising, in-game media products, and direct-to-consumer offers, aimed at enhancing user engagement through dynamic programming.

Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly severe respiratory conditions. Founded in 2010 and headquartered in Durham, North Carolina, the company specializes in a proprietary handheld soft mist device that delivers insulin directly into the lungs. This device enables patients to administer their medication with ease, achieving high lung deposition and distribution in just a few breaths. Aerami's focus extends beyond diabetes; it aims to improve the effectiveness of inhaled drugs for various conditions, including pulmonary arterial hypertension, thereby enhancing clinical outcomes and reducing treatment times for patients.

Clover Inc., established in 2014 and headquartered in Toronto, Canada, develops a mobile dating application designed to facilitate high-quality connections between users with minimal effort. The platform enables users to browse potential matches locally or globally, get matched based on preferences, find suitable date locations, and confirm meeting details directly through the app.

Amplifica is a preclinical stage biopharmaceutical company dedicated to developing innovative treatments for androgenic alopecia, commonly known as hair loss. The company employs a nature-inspired scientific approach that leverages unique signaling molecules to stimulate hair follicle regeneration. By focusing on these molecular mechanisms, Amplifica aims to provide healthcare professionals with effective solutions for treating hair loss, thereby addressing a significant unmet medical need in this area.

Orchestra BioMed is a biomedical innovation company based in New Hope, Pennsylvania, founded in 2017. The company specializes in developing high-impact therapeutic solutions for major medical conditions, with a primary focus on cardiovascular diseases, which are responsible for approximately 31% of global deaths annually. Orchestra BioMed's business model involves strategic partnerships with medical device companies to accelerate the commercialization of its products. Its key product candidates include BackBeat Cardiac Neuromodulation Therapy for hypertension and Virtue Sirolimus AngioInfusionBalloon for atherosclerotic artery disease.

Psudo is a sustainable sneaker brand based in Saint Louis, Missouri, founded in 2021. The company focuses on manufacturing lightweight sneakers that are locally sourced and constructed from eco-friendly recycled materials. Designed for all-day wear, Psudo's footwear features antimicrobial properties and anatomically supportive structures, ensuring comfort and durability. By prioritizing sustainability, the company aims to provide affordable options for consumers seeking environmentally conscious footwear solutions.

Outstanding Foods, Inc. is a Los Angeles-based company specializing in the production of plant-based vegan snacks. Founded in 2015 and originally known as Fresh Soul Holdings, Inc., the company rebranded in 2017. Outstanding Foods offers a variety of products under its PigOut Rinds and TakeOut Puffs brands, focusing on creating flavorful, guilt-free snacks crafted from pure, wholesome ingredients. Their offerings, including chef-crafted crispy bacon chips, are designed to be high in protein and free from animal ingredients, allowing customers to enjoy nutritious and delicious food options without compromise.

Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly severe respiratory conditions. Founded in 2010 and headquartered in Durham, North Carolina, the company specializes in a proprietary handheld soft mist device that delivers insulin directly into the lungs. This device enables patients to administer their medication with ease, achieving high lung deposition and distribution in just a few breaths. Aerami's focus extends beyond diabetes; it aims to improve the effectiveness of inhaled drugs for various conditions, including pulmonary arterial hypertension, thereby enhancing clinical outcomes and reducing treatment times for patients.

DermaSensor, Inc. is a Miami-based company that specializes in developing innovative technology for skin cancer evaluation. Founded in 2009, the company has created a handheld device that employs artificial intelligence, machine learning, and elastic scattering spectroscopy to assess skin lesions for potential cancer. This device enables both physicians and consumers to perform skin checks in various settings, including clinics and at home. By providing an efficient and affordable solution for early skin cancer detection, DermaSensor aims to improve access to vital healthcare services and reduce the costs associated with skin cancer diagnosis. The technology not only identifies cancerous cells but also sends alerts when such cells are detected, facilitating timely intervention.

Viscient Biosciences is a biotechnology company based in San Diego, California, founded in 2017 by former scientists and entrepreneurs from Organovo and Ardea Biosciences. The company specializes in drug discovery and development using human 3D tissue technology combined with multi-omics analysis, which includes genomics, transcriptomics, and metabolomics. This approach allows Viscient to identify genes and pathways that drive disease progression, initially focusing on non-alcoholic steatohepatitis (NASH), commonly known as fatty liver disease. By leveraging this innovative platform, Viscient aims to revolutionize drug discovery beyond traditional animal models.

Zoomcar is a leading car-sharing marketplace operating primarily in emerging markets, with over 20,000 cars available on its technology-driven platform across India, Southeast Asia, and Egypt. The company enables host entrepreneurs to share their vehicles safely and easily, generating additional passive income. Guests benefit from a wide range of affordable cars for memorable driving experiences. Founded in 2013 and based in Bengaluru, India, Zoomcar employs over 300 people and serves 50 cities across India, Indonesia, Vietnam, and Egypt. Uri Levine, co-founder of mobility companies Waze and Moovit, is the Chairman of the Board. The company's revenue comes mainly from short-term self-drive rentals and vehicle subscriptions, with a significant portion derived from its operations in India.

Hydrobuilder.com offers a large selection of indoor grow lights, complete hydroponic system, plant nutrients, ventilation systems, grow tents and more! Hydrobuilder supplies both hobby and commercial cultivators in all 50 states.

Zoomcar is a leading car-sharing marketplace operating primarily in emerging markets, with over 20,000 cars available on its technology-driven platform across India, Southeast Asia, and Egypt. The company enables host entrepreneurs to share their vehicles safely and easily, generating additional passive income. Guests benefit from a wide range of affordable cars for memorable driving experiences. Founded in 2013 and based in Bengaluru, India, Zoomcar employs over 300 people and serves 50 cities across India, Indonesia, Vietnam, and Egypt. Uri Levine, co-founder of mobility companies Waze and Moovit, is the Chairman of the Board. The company's revenue comes mainly from short-term self-drive rentals and vehicle subscriptions, with a significant portion derived from its operations in India.

Outstanding Foods, Inc. is a Los Angeles-based company specializing in the production of plant-based vegan snacks. Founded in 2015 and originally known as Fresh Soul Holdings, Inc., the company rebranded in 2017. Outstanding Foods offers a variety of products under its PigOut Rinds and TakeOut Puffs brands, focusing on creating flavorful, guilt-free snacks crafted from pure, wholesome ingredients. Their offerings, including chef-crafted crispy bacon chips, are designed to be high in protein and free from animal ingredients, allowing customers to enjoy nutritious and delicious food options without compromise.

DarioHealth, established in 2011 and headquartered in Caesarea, Israel, is a digital health company specializing in the development and commercialization of patented technologies for mobile, real-time health monitoring. Its flagship product, Dario, is a comprehensive diabetes management solution comprising a pocket-sized blood glucose monitoring device and a multi-featured software application. DarioHealth markets its products directly to consumers and through retail channels, generating revenue primarily from the sale of its smart meters and related disposable test strips and lancets. The company's digital platform, DarioEngage, engages users, provides coaching and support, and offers real-time alerts and trend analysis for chronic illness management. DarioHealth operates internationally, with a presence in the United States, Europe, Australia, and Canada.

Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on creating and commercializing innovative anti-cancer therapies for patients with unmet medical needs. The company is advancing two late-stage therapeutics: VAL-083, a DNA-targeting agent designed to treat drug-resistant solid tumors such as glioblastoma multiforme and ovarian cancer, and REM-001, a photodynamic therapy aimed at cutaneous metastatic breast cancer. Kintara has established a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and sales of VAL-083 in China. Kintara Therapeutics was founded in 2009 and is headquartered in San Diego, California. The company seeks to address significant challenges faced by cancer patients who have not responded to conventional treatments.

DermaSensor, Inc. is a Miami-based company that specializes in developing innovative technology for skin cancer evaluation. Founded in 2009, the company has created a handheld device that employs artificial intelligence, machine learning, and elastic scattering spectroscopy to assess skin lesions for potential cancer. This device enables both physicians and consumers to perform skin checks in various settings, including clinics and at home. By providing an efficient and affordable solution for early skin cancer detection, DermaSensor aims to improve access to vital healthcare services and reduce the costs associated with skin cancer diagnosis. The technology not only identifies cancerous cells but also sends alerts when such cells are detected, facilitating timely intervention.

Outstanding Foods, Inc. is a Los Angeles-based company specializing in the production of plant-based vegan snacks. Founded in 2015 and originally known as Fresh Soul Holdings, Inc., the company rebranded in 2017. Outstanding Foods offers a variety of products under its PigOut Rinds and TakeOut Puffs brands, focusing on creating flavorful, guilt-free snacks crafted from pure, wholesome ingredients. Their offerings, including chef-crafted crispy bacon chips, are designed to be high in protein and free from animal ingredients, allowing customers to enjoy nutritious and delicious food options without compromise.

Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly severe respiratory conditions. Founded in 2010 and headquartered in Durham, North Carolina, the company specializes in a proprietary handheld soft mist device that delivers insulin directly into the lungs. This device enables patients to administer their medication with ease, achieving high lung deposition and distribution in just a few breaths. Aerami's focus extends beyond diabetes; it aims to improve the effectiveness of inhaled drugs for various conditions, including pulmonary arterial hypertension, thereby enhancing clinical outcomes and reducing treatment times for patients.

DarioHealth, established in 2011 and headquartered in Caesarea, Israel, is a digital health company specializing in the development and commercialization of patented technologies for mobile, real-time health monitoring. Its flagship product, Dario, is a comprehensive diabetes management solution comprising a pocket-sized blood glucose monitoring device and a multi-featured software application. DarioHealth markets its products directly to consumers and through retail channels, generating revenue primarily from the sale of its smart meters and related disposable test strips and lancets. The company's digital platform, DarioEngage, engages users, provides coaching and support, and offers real-time alerts and trend analysis for chronic illness management. DarioHealth operates internationally, with a presence in the United States, Europe, Australia, and Canada.

Orchestra BioMed is a biomedical innovation company based in New Hope, Pennsylvania, founded in 2017. The company specializes in developing high-impact therapeutic solutions for major medical conditions, with a primary focus on cardiovascular diseases, which are responsible for approximately 31% of global deaths annually. Orchestra BioMed's business model involves strategic partnerships with medical device companies to accelerate the commercialization of its products. Its key product candidates include BackBeat Cardiac Neuromodulation Therapy for hypertension and Virtue Sirolimus AngioInfusionBalloon for atherosclerotic artery disease.

Hydrofarm is a leading distributor and manufacturer of controlled environment agriculture equipment and supplies, focusing on enhancing the productivity and efficiency of growers, farmers, and cultivators. With over 40 years of experience, the company offers a diverse range of products, including high-intensity grow lights, climate control solutions, premium soils, and nutrients, marketed under both proprietary and distributed brands. Hydrofarm operates primarily in the U.S. and Canadian markets, providing innovative solutions that support the needs of the agriculture community. By prioritizing quality and consistency, Hydrofarm aims to empower its customers in their growing endeavors.

Orchestra BioMed is a biomedical innovation company based in New Hope, Pennsylvania, founded in 2017. The company specializes in developing high-impact therapeutic solutions for major medical conditions, with a primary focus on cardiovascular diseases, which are responsible for approximately 31% of global deaths annually. Orchestra BioMed's business model involves strategic partnerships with medical device companies to accelerate the commercialization of its products. Its key product candidates include BackBeat Cardiac Neuromodulation Therapy for hypertension and Virtue Sirolimus AngioInfusionBalloon for atherosclerotic artery disease.

BackBeat Medical Inc. is a medical technology company established in 2010, focused on developing innovative cardiac stimulation-based therapies specifically for hypertension and heart failure. The company has created a patented treatment known as programmable hypertension control (PHC) therapy, which utilizes proprietary pacing algorithms that can be integrated into standard pacemakers with conventional leads and placements. This technology presents a new, potent therapeutic option for patients with hypertension, particularly those who already require a pacemaker. Clinical studies of BackBeat's Moderato™ pacemaker, which incorporates PHC algorithms, have shown significant and sustained reductions in blood pressure, with average decreases of 24 mmHg in office settings and 14 mmHg in 24-hour ambulatory monitoring, demonstrating efficacy over extended follow-up periods. BackBeat Medical's PHC therapy is supported by a comprehensive global patent portfolio, positioning the company for potential growth in the hypertension treatment market.

Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly severe respiratory conditions. Founded in 2010 and headquartered in Durham, North Carolina, the company specializes in a proprietary handheld soft mist device that delivers insulin directly into the lungs. This device enables patients to administer their medication with ease, achieving high lung deposition and distribution in just a few breaths. Aerami's focus extends beyond diabetes; it aims to improve the effectiveness of inhaled drugs for various conditions, including pulmonary arterial hypertension, thereby enhancing clinical outcomes and reducing treatment times for patients.

Adgero Biopharmaceuticals is a biopharmaceutical company focused on developing innovative photodynamic therapy (PDT) for the treatment of serious oncology indications, particularly rare and unmet medical needs in cancer. Founded in 2007 and headquartered in Pittstown, New Jersey, Adgero's lead product, REM-001 Therapy, utilizes a combination of laser light, a light delivery device, and a drug to target cutaneous metastatic cancers. The therapy has shown promising safety and efficacy results in Phase 2/3 clinical trials, specifically for patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. The company's ongoing research aims to leverage existing data and complete further clinical trials to facilitate potential regulatory approval for REM-001, thereby expanding treatment options for patients suffering from serious skin cancers.

Caliber Therapeutics, Inc. is focused on developing and commercializing minimally-invasive balloon-based drug delivery products aimed at treating atherosclerotic diseases. The company's flagship product, the Targeted Angioplasty Drug Delivery balloon, serves as a stent-free platform for the controlled and targeted delivery of anti-restenotic drugs. This innovative approach not only enhances treatment effectiveness but also minimizes the risk of thrombosis and reduces the necessity for permanent device implantation. Headquartered in Monmouth Junction, New Jersey, Caliber Therapeutics seeks to improve patient outcomes through its advanced drug-delivery solutions.

Motus GI Holdings, Inc. is a medical technology company based in Fort Lauderdale, Florida, with operations in the United States and Israel. The company specializes in developing endoscopy solutions aimed at improving clinical outcomes and reducing costs associated with gastrointestinal conditions. Its primary product, the Pure-Vu System, is designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures, thereby enhancing the overall patient experience and aiding in the early detection of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and holds CE marking for use in the European Economic Area.

Helocyte Inc. is a biotechnology company dedicated to the development and commercialization of innovative immunotherapies for the prevention and treatment of cytomegalovirus (CMV). The company is advancing three primary immunotherapy programs: PepVax, a peptide vaccine designed for allogeneic hematopoietic stem cell transplant recipients; Triplex, a universal recombinant viral vector vaccine targeting multiple CMV proteins, also intended for allogeneic HSCT recipients and potentially for solid organ transplant recipients; and Pentamer, another universal vaccine aimed at preventing congenital CMV transmission. Helocyte has established exclusive rights to these technologies through an agreement with City of Hope, where the therapies were developed. The company is focused on funding research and development to bring these promising therapies to market, ultimately aiming to improve patient outcomes in those at risk of CMV-related complications.

Adgero Biopharmaceuticals is a biopharmaceutical company focused on developing innovative photodynamic therapy (PDT) for the treatment of serious oncology indications, particularly rare and unmet medical needs in cancer. Founded in 2007 and headquartered in Pittstown, New Jersey, Adgero's lead product, REM-001 Therapy, utilizes a combination of laser light, a light delivery device, and a drug to target cutaneous metastatic cancers. The therapy has shown promising safety and efficacy results in Phase 2/3 clinical trials, specifically for patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. The company's ongoing research aims to leverage existing data and complete further clinical trials to facilitate potential regulatory approval for REM-001, thereby expanding treatment options for patients suffering from serious skin cancers.

Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on creating and commercializing innovative anti-cancer therapies for patients with unmet medical needs. The company is advancing two late-stage therapeutics: VAL-083, a DNA-targeting agent designed to treat drug-resistant solid tumors such as glioblastoma multiforme and ovarian cancer, and REM-001, a photodynamic therapy aimed at cutaneous metastatic breast cancer. Kintara has established a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and sales of VAL-083 in China. Kintara Therapeutics was founded in 2009 and is headquartered in San Diego, California. The company seeks to address significant challenges faced by cancer patients who have not responded to conventional treatments.

Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly severe respiratory conditions. Founded in 2010 and headquartered in Durham, North Carolina, the company specializes in a proprietary handheld soft mist device that delivers insulin directly into the lungs. This device enables patients to administer their medication with ease, achieving high lung deposition and distribution in just a few breaths. Aerami's focus extends beyond diabetes; it aims to improve the effectiveness of inhaled drugs for various conditions, including pulmonary arterial hypertension, thereby enhancing clinical outcomes and reducing treatment times for patients.

Corbus Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, focused on developing and commercializing therapeutics for the treatment of rare and serious inflammatory fibrotic diseases. Founded in 2009, the company’s lead product candidate, lenabasum, is a synthetic, orally administered cannabinoid receptor type 2 (CB2) agonist currently undergoing Phase III clinical trials for systemic sclerosis and dermatomyositis, as well as Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. Additionally, Corbus is developing CRB-4001, a peripherally-restricted cannabinoid receptor type 1 (CB1) inverse agonist, aimed at treating nonalcoholic steatohepatitis and other fibrotic conditions. The company has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the commercialization of lenabasum in Japan and has a licensing agreement with Jenrin Discovery, LLC to utilize a library of novel compounds targeting the endocannabinoid system. With a commitment to addressing chronic inflammation and fibrotic diseases, Corbus Pharmaceuticals is advancing its pipeline of innovative drug candidates.

Matinas BioPharma is a clinical-stage biopharmaceutical company based in Bedminster, New Jersey, that specializes in the discovery and development of therapeutics for fungal and bacterial infections. The company utilizes a proprietary lipid nano-crystal drug delivery platform, known as cochleate delivery technology, to create orally delivered therapeutics. Its lead product candidate, MAT2203, is an oral formulation of amphotericin B currently in Phase II trials for treating invasive fungal infections. Additionally, Matinas is developing MAT2501, an encochleated formulation of amikacin aimed at addressing multidrug-resistant bacterial infections. The company's pipeline also includes MAT9001, an omega-3 fatty acid formulation for hypertriglyceridemia, and it is exploring options for its MAT8800 discovery program targeting non-alcoholic fatty liver disease. Matinas has established research collaborations with notable organizations, including the National Institute of Neurological Disorders and Stroke and ViiV Healthcare, to advance its therapeutic developments.

DarioHealth, established in 2011 and headquartered in Caesarea, Israel, is a digital health company specializing in the development and commercialization of patented technologies for mobile, real-time health monitoring. Its flagship product, Dario, is a comprehensive diabetes management solution comprising a pocket-sized blood glucose monitoring device and a multi-featured software application. DarioHealth markets its products directly to consumers and through retail channels, generating revenue primarily from the sale of its smart meters and related disposable test strips and lancets. The company's digital platform, DarioEngage, engages users, provides coaching and support, and offers real-time alerts and trend analysis for chronic illness management. DarioHealth operates internationally, with a presence in the United States, Europe, Australia, and Canada.

Armada Water Assets is a fully integrated service company based in Houston, Texas, specializing in water supply, collection, and remediation services. Founded in 2012, the company focuses on the safe and cost-effective management of contaminated water generated from conventional oil and gas production, as well as hydraulic fracturing flow-back water. Armada provides comprehensive solutions for the collection, handling, transport, treatment, and reuse of this produced water, addressing the needs of oil and gas production companies while promoting environmental sustainability.

Deem, Inc. is a technology company specializing in Commerce-as-a-Service (CaaS) solutions tailored for the business travel industry. Founded in 1999 and headquartered in San Francisco, California, Deem offers a comprehensive cloud-based suite of applications that streamline travel, expense management, and purchasing for companies. Its platform empowers organizations to manage travel bookings for flights, hotels, and ground transportation while ensuring compliance with corporate spending policies. Additionally, Deem enables merchants to effectively promote and sell their products and services through various channels, enhancing customer engagement with options such as card-linked offers and corporate discounts. The company's focus is on simplifying business travel for employees, reducing costs for employers, and creating profitable opportunities for service providers. Deem operates as a subsidiary of Enterprise Holdings, Inc.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, specializing in the development of therapeutic products for cancer and infectious diseases utilizing its proprietary Tarmogen platform. Founded in 1995 as Ceres Pharmaceuticals, the company focuses on creating targeted molecular immunotherapies. Its product pipeline includes GS-4774, currently in Phase 2 trials for chronic hepatitis B infection, and GI-6301, aimed at cancers expressing the brachyury protein. Additionally, GlobeImmune is advancing GI-6207 for medullary thyroid cancer and GI-4000 for resected pancreatic cancer, with multiple Phase 2 clinical trials for various other cancers, including non-small cell lung cancer and colorectal cancer. The company is also developing several candidates targeting infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D, which are in preclinical stages. GlobeImmune has established strategic collaborations with notable organizations, enhancing its research and development efforts.

Organovo Holdings, Inc. is a biotechnology company specializing in the development of bioprinted human tissues utilizing its advanced 3D human tissue platform technology. This platform features proprietary NovoGen Bioprinters, which automate the fabrication of living tissues made from mammalian cells. Organovo produces ExVive human liver and kidney tissues that facilitate predictive preclinical drug testing. The company is also working on in vivo liver tissues aimed at treating end-stage liver diseases and is developing a NovoTissues liver product that incorporates cells from both liver and umbilical cord donors. Founded in 2007 and based in Solana Beach, California, Organovo is dedicated to addressing unmet medical needs through innovative regenerative medicine solutions.

InVivo Therapeutics Corporation is a medical device company dedicated to developing innovative treatments aimed at restoring function in individuals affected by traumatic spinal cord injuries. Founded in 2005, the company harnesses polymers as a platform technology to create advanced biomaterials and biotechnology solutions. Its product pipeline includes the Neuro spinal scaffold and Bioengineered neural trails, which are designed for the treatment of acute spinal cord injuries, as well as a preclinical development program targeting chronic spinal cord injuries. Based in Cambridge, Massachusetts, InVivo Therapeutics is focused on research and clinical initiatives to advance its mission of improving the quality of life for those impacted by spinal cord damage.

PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.

Psudo is a sustainable sneaker brand based in Saint Louis, Missouri, founded in 2021. The company focuses on manufacturing lightweight sneakers that are locally sourced and constructed from eco-friendly recycled materials. Designed for all-day wear, Psudo's footwear features antimicrobial properties and anatomically supportive structures, ensuring comfort and durability. By prioritizing sustainability, the company aims to provide affordable options for consumers seeking environmentally conscious footwear solutions.